CELU logo

Celularity Inc. Stock Price

NasdaqCM:CELU Community·US$54.7m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

CELU Share Price Performance

US$2.05
-0.72 (-25.99%)
US$2.05
-0.72 (-25.99%)
Price US$2.05

CELU Community Narratives

There are no narratives available yet.

Recent CELU News & Updates

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 59%

Aug 14
Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 59%

Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry

Feb 21
Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry

Celularity Inc. Key Details

US$44.6m

Revenue

US$20.0m

Cost of Revenue

US$24.6m

Gross Profit

US$98.2m

Other Expenses

-US$73.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-2.76
Gross Margin
55.10%
Net Profit Margin
-165.21%
Debt/Equity Ratio
-170.4%

Celularity Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Slight risk and slightly overvalued.

4 Risks
1 Reward

About CELU

Founded
1998
Employees
123
CEO
Robert Hariri
WebsiteView website
www.celularity.com

Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn’s disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn’s) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 5.1%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a decline of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›